Balyasny Asset Management LLC Achilles Therapeutics PLC Transaction History

Balyasny Asset Management LLC

  • $72.4 Billion
  • Q3 2025

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$2.26 - $3.38 $38,553 - $57,659
17,059 New
17,059 $39,000

Others Institutions Holding ACHL

# of Institutions
3
Shares Held
7.29K
Call Options Held
0
Put Options Held
0
View Full List

About Achilles Therapeutics plc

ACHL Quotes by TradingView
  • Ticker ACHL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,774,000
  • Market Cap $60.3M
  • Description
  • Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...
More about ACHL
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email